These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39394613)

  • 1. Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis.
    Ji X; Zhang A; Duan X; Wang Q
    Radiat Oncol; 2024 Oct; 19(1):143. PubMed ID: 39394613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study.
    Ji X; Xu Z; Sun J; Li W; Duan X; Wang Q
    Radiat Oncol; 2023 Jun; 18(1):101. PubMed ID: 37308914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis.
    Wang Q; Ji X; Sun J; Li W; Duan X; Zhang A
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7441-7452. PubMed ID: 36952005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.
    Shui Y; Yu W; Ren X; Guo Y; Xu J; Ma T; Zhang B; Wu J; Li Q; Hu Q; Shen L; Bai X; Liang T; Wei Q
    Radiat Oncol; 2018 Sep; 13(1):188. PubMed ID: 30253783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram.
    Li X; Ye Z; Lin S; Pang H
    BMC Cancer; 2021 Jun; 21(1):701. PubMed ID: 34126955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Li LQ; Zhou Y; Huang Y; Liang P; Liang SX; Su TS
    Hepatol Int; 2021 Jun; 15(3):630-641. PubMed ID: 33818714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: Feasibility and clinical outcomes.
    Khorprasert C; Thonglert K; Alisanant P; Amornwichet N
    PLoS One; 2021; 16(9):e0257556. PubMed ID: 34555075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching.
    Tang C; He Q; Feng J; Liao Z; Peng Y; Gao J
    Front Immunol; 2023; 14():1254158. PubMed ID: 37928530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
    Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C
    Hepatol Int; 2024 Aug; 18(4):1286-1298. PubMed ID: 38717693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis.
    Que J; Wu HC; Lin CH; Huang CI; Li LC; Ho CH
    Medicine (Baltimore); 2020 Mar; 99(13):e19660. PubMed ID: 32221093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib
    Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.
    Nakazawa T; Hidaka H; Shibuya A; Okuwaki Y; Tanaka Y; Takada J; Minamino T; Watanabe M; Kokubu S; Koizumi W
    BMC Gastroenterol; 2014 May; 14():84. PubMed ID: 24886354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
    Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study.
    Ou X; Wu J; Wu J; Fu Y; Zeng Z; Li S; Li Y; Liu D; Li H; Li B; Zhou J; Zhuang S; Cheng S; Zhang Z; Wang K; Qu S; Yan M
    Cancer Res Treat; 2024 Oct; 56(4):1207-1218. PubMed ID: 38697847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis.
    Mukozu T; Nagai H; Matsui D; Mohri K; Watanabe G; Yoshimine N; Amanuma M; Kobayashi K; Ogino Y; Matsukiyo Y; Matsui T; Daido Y; Wakui N; Shinohara M; Momiyama K; Higai K; Igarashi Y
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):11-20. PubMed ID: 34628536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy?
    Srivastava A; Parambath HK; Ramdulari AV; Saxena H; Kumar R; Pandey S; Shalimar ; Gupta S; Jee B
    Int J Radiat Biol; 2022; 98(10):1495-1509. PubMed ID: 35311612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.